Article
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
Clinical lung cancer - 1 Mar 2026
Li Bob T, Gandhi Leena, Ravichandran Vignesh, Besse Benjamin, Mazières Julien, Shapiro Geoffrey I, Boni Valentina, Waqar Saiama N, Park Haeseong, Quinn David I, Martinez Alejandro, Stemmer Salomon M, Cortot Alexis B, Barlesi Fabrice, Quoix Elisabeth, Burkard Mark E, Selcuklu S Duygu, Hunt Casey, Donoghue Mark T A, Kris Mark G, Bebchuk Judith, Eli Lisa D, McCulloch Leanne, Solit David B, Jänne Pasi A
Abstract excerpt
BACKGROUND: ERBB2 mutations are oncogenic drivers in 2% to 4% of lung cancers and potentially actionable using HER2 tyrosine kinase inhibitors. PATIENTS AND METHODS: Patients with advanced ERBB2-mutant lung cancer entered 2 phase 2 studies (PUMA-NER-4201 [4201]; PUMA-NER-5201 [SUMMIT]). Patients received neratinib (monotherapy 4201; monotherapy SUMMIT), or neratinib with weekly temsirolimus (combination 4201), or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.